Glioblastoma Multiforme (GBM) Clinical Trials

11 recruiting

Glioblastoma Multiforme (GBM) Trials at a Glance

11 actively recruiting trials for glioblastoma multiforme (gbm) are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 1 with 6 trials, with the heaviest enrollment activity in Sutton, Zhengzhou, and Beijing. Lead sponsors running glioblastoma multiforme (gbm) studies include Institute of Cancer Research, United Kingdom, Peking University Third Hospital, and Filamon LTD.

Browse glioblastoma multiforme (gbm) trials by phase

Treatments under study

About Glioblastoma Multiforme (GBM) Clinical Trials

Looking for clinical trials for Glioblastoma Multiforme (GBM)? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Glioblastoma Multiforme (GBM) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Glioblastoma Multiforme (GBM) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled4 locationsNCT07326566
Recruiting
Not Applicable

NK Cell Therapy for Malignant Solid Brain Tumors

Brain MetastasisGlioblastoma Multiforme (GBM)Glioblastoma (GBM)+2 more
Peking University Third Hospital27 enrolled4 locationsNCT07552233
Recruiting
Phase 3

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

GlioblastomaNeoplastic DiseaseGlioblastoma (GBM)+3 more
Telix Pharmaceuticals (Innovations) Pty Limited50 enrolled4 locationsNCT07100730
Recruiting
Phase 1Phase 2

Early Phase Study of KESONOTIDE™in Participants With Solid Tumours

Breast CancerLung CancersOvarian Cancer+4 more
Filamon LTD80 enrolled3 locationsNCT06926075
Recruiting
Phase 1Phase 2

5G-PEARL: Paxalisib in Malignant Brain Tumours

Glioblastoma Multiforme (GBM)Malignant Primary Gliomas
Institute of Cancer Research, United Kingdom64 enrolled1 locationNCT07391215
Recruiting
Phase 1Phase 2

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

Glioblastoma Multiforme (GBM)Malignant Primary GliomasGlioblastoma Multiform (Grade IV Astrocytoma)+1 more
Institute of Cancer Research, United Kingdom182 enrolled3 locationsNCT06630260
Recruiting
Phase 1

Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy

Glioblastoma Multiforme (GBM)GBMGlioma+5 more
Sunnybrook Health Sciences Centre10 enrolled1 locationNCT07179328
Recruiting
Not Applicable

Allogeneic γδT Cells in Glioblastoma

Glioblastoma Multiforme (GBM)Glioblastoma (GBM)
Peking University Third Hospital18 enrolled3 locationsNCT07144735
Recruiting
Phase 1

5G-EMERALD: Amivantamab in Malignant Brain Tumours

Glioblastoma Multiforme (GBM)Malignant Primary GliomasGlioblastoma Multiform (Grade IV Astrocytoma)+1 more
Institute of Cancer Research, United Kingdom12 enrolled2 locationsNCT06632236
Recruiting
Phase 1Phase 2

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

CancerBrain TumorBrain Cancer+6 more
Northwell Health67 enrolled1 locationNCT03213002
Recruiting
Phase 2

JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme (GBM)
JenKem Technology Co., Ltd.25 enrolled1 locationNCT06595186